CureVac GmbH - Product Pipeline Review - 2016

Date: April 20, 2016
Pages: 49
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C50B0F13897EN
Leaflet:

Download PDF Leaflet

CureVac GmbH - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘CureVac GmbH - Product Pipeline Review - 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH
  • The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses CureVac GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features CureVac GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate CureVac GmbH’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for CureVac GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CureVac GmbH’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
CureVac GmbH Snapshot
CureVac GmbH Overview
Key Information
Key Facts
CureVac GmbH - Research and Development Overview
Key Therapeutic Areas
CureVac GmbH - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
CureVac GmbH - Pipeline Products Glance
CureVac GmbH - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CureVac GmbH - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
CureVac GmbH - Drug Profiles
CV-9104
Product Description
Mechanism of Action
R&D Progress
CV-9103
Product Description
Mechanism of Action
R&D Progress
CV-9201
Product Description
Mechanism of Action
R&D Progress
CV-8102
Product Description
Mechanism of Action
R&D Progress
nadorameran
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Cancer
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Infectious Disease
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Influenza Virus Infection
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for respiratory syncytial virus vaccine
Product Description
Mechanism of Action
R&D Progress
infectious disease vaccine
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for HIV
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Respiratory Syncytial Virus-1 Infection
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Rotavirus Infection
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Oligonucleotides for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Vaccine 1 for oncology
Product Description
Mechanism of Action
R&D Progress
Vaccine for Oncology
Product Description
Mechanism of Action
R&D Progress
CureVac GmbH - Pipeline Analysis
CureVac GmbH - Pipeline Products by Target
CureVac GmbH - Pipeline Products by Route of Administration
CureVac GmbH - Pipeline Products by Molecule Type
CureVac GmbH - Recent Pipeline Updates
CureVac GmbH - Dormant Projects
CureVac GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

CureVac GmbH, Key Information
CureVac GmbH, Key Facts
CureVac GmbH - Pipeline by Indication, 2016
CureVac GmbH - Pipeline by Stage of Development, 2016
CureVac GmbH - Monotherapy Products in Pipeline, 2016
CureVac GmbH - Partnered Products in Pipeline, 2016
CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2016
CureVac GmbH - Out-Licensed Products in Pipeline, 2016
CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
CureVac GmbH - Phase II, 2016
CureVac GmbH - Phase I, 2016
CureVac GmbH - Preclinical, 2016
CureVac GmbH - Discovery, 2016
CureVac GmbH - Pipeline by Target, 2016
CureVac GmbH - Pipeline by Route of Administration, 2016
CureVac GmbH - Pipeline by Molecule Type, 2016
CureVac GmbH - Recent Pipeline Updates, 2016
CureVac GmbH - Dormant Developmental Projects,2016
CureVac GmbH, Other Locations

LIST OF FIGURES

CureVac GmbH - Pipeline by Top 10 Indication, 2016
CureVac GmbH - Pipeline by Stage of Development, 2016
CureVac GmbH - Monotherapy Products in Pipeline, 2016
CureVac GmbH - Out-Licensed Products in Pipeline, 2016
CureVac GmbH - Pipeline by Top 10 Target, 2016
CureVac GmbH - Pipeline by Route of Administration, 2016
CureVac GmbH - Pipeline by Molecule Type, 2016
Skip to top


RESprotect GmbH - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 28 pages
Recardio GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 24 pages
Pharmedartis GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 24 pages
ElexoPharm GmbH - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 24 pages
BioCrea GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 24 pages

Ask Your Question

CureVac GmbH - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: